Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
completed

Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients

key information

study id #: NCT00844597

condition: Duchenne Muscular Dystrophy

status: completed

purpose:

The specific aim of this Phase I/II study is to assess the safety of intravenous administered Morpholino oligomer directed against exon 51 (AVI-4658 PMO).

intervention: AVI-4658 for Injection

results: https://clinicaltrials.gov/ct2/show/results/NCT00844597

study details

start date: January 2009

estimated completion: June 2010

phase of development: Phase 1/Phase 2

size / enrollment: 19

study description:
Primary outcome is safety, tolerability and dose selection for future studies.

primary outcomes:

  • Safety and Tolerability [ Time Frame: Baseline to 6 months ]
    Number of subjects with 1 or more Treatment Emergent Adverse Event that are possibly related to the investigational drug
  • Treatment Emergent Adverse Events [ Time Frame: from Baseline to Follow up (27 weeks) ]
    Number of Patients with Treatment Emergent Adverse Events

secondary outcomes:

  • Pharmacokinetics - Mean Peak Plasma Concentration of AVI-4658 After Administration [ Time Frame: Samples were taken: 30 minutes pre dose; and at 5 (±1), 15 (±2), 30 (±5), 60 (±5), and 90 (±5) minutes; and 2, 4, 6, 8, 12, and 24 hours (all ± 15 minutes) post dose at Weeks 1, 6, and 12 ]
    Standard Pharmacokinetic parameters estimated using non-compartmental modeling of plasma concentration data.
  • Efficacy of Eteplirsen Over 12 Weeks of Dosing [ Time Frame: Biopsies were taken at Baseline and Week 14 ]
    Efficacy was defined as an estimated change in the percentage of dystrophin positive fibers (assessed by IHC) at Week 14 from Baseline after 12 weekly doses of eterplirsen. This outcome measure represents the number of patients to show an increase in the percentage of dystrophin-positive fibers.

inclusion criteria:
• Has provided written informed assent (as required by EC) and parents/guardians have provided written informed consent.
• Has an out-of-frame deletion(s) that could be corrected by skipping exon 51 based on DNA sequencing data from the candidate.
• Is male and between the ages of >= 5 years and <= 15 years.
• Has a muscle biopsy analysis showing < 5% revertant fibres present at baseline.
• DNA sequencing of the candidate's dystrophin exon 51 confirms that no DNA polymorphisms are present that could compromise PMO duplex formation or there is confirmation of in vitro dystrophin production after AVI-4658 exposure to fibroblast or myoblast in vitro cultures.
• Intact right and left bicep muscles or alternative arm muscle group.
• Is able to walk independently at least 25 meters.
• Has a forced vital capacity (FVC) >= 50% of predicted and does not require ventilatory support or supplemental oxygen.
• Receives the standard of care for DMD as recommended by the DMD care recommendations from the North Star UK and TREAT-NMD.
• The parent(s) or legal guardian and Subject have undergone counselling about the expectations of this protocol and agree to participate.
• The parent(s) or legal guardian and Subject intend to comply with all study evaluations and return for all study activities.

exclusion criteria:
• A DNA polymorphism within exon 51 that may compromise PMO duplex formation.
• Known antibodies to dystrophin.
• Lacks intact right and left bicep muscles or alternative arm muscle group.
• A calculated creatinine clearance less than 70% of predicted normal for age based on the Cockcroft and Gault Formula.
• A left ventricular ejection fraction (EF) of < 35% and/or fractional shortening of <25% based on echocardiography (ECHO)during screening.
• A history of respiratory insufficiency as defined by need for intermittent or continuous supplemental oxygen.
• A severe cognitive dysfunction rendering the potential subject unable to understand and comply with the study protocol.
• Any known immune deficiency or autoimmune disease.
• A known bleeding disorder or has received chronic anticoagulant treatment within three months of study entry.
• Receipt of pharmacologic treatment, apart from corticosteroids, that might affect muscle strength or function within 8 weeks of study entry (viz., growth hormone, anabolic steroids).
• Surgery within 3 months of study entry or planned for anytime during the duration of the study.
• Another clinically significant illness at time of study entry.
• Subject or parent has active psychiatric disorder, has adverse psychosocial circumstances,recent significant emotional loss, and/or history of depressive or anxiety disorder that might interfere with protocol compliance.
• Use of any experimental treatments, has participated in any DMD interventional clinical trial within 4 weeks of study entry

study contacts

sponsor: Sarepta Therapeutics

investigators: Austen Eddy, MSM

locations: United Kingdom